David D. Douglas

TL;DR: Patients with perihilar cholangiocarcinoma who were treated with neoadjuvant therapy followed up by liver transplantation at 12 US centers had a 65% rate of recurrence-free survival after 5 years, showing this therapy to be highly effective.

TL;DR: A national conference was held to better characterize the long‐term outcomes of liver transplantation for patients with hepatocellular carcinoma (HCC) and to assess whether it is justified to continue the policy of assigning increased priority for candidates with early‐stage HCC on the transplant waiting list in the United States.

TL;DR: The 6MWD is significantly reduced in patients awaiting LT and is inversely correlated with the native MELD score, which is commonly used to predict mortality in patients with cardiac and pulmonary diseases.

TL;DR: Adefovir dipivoxil is effective and safe in wait‐listed or post–liver transplantation chronic hepatitis B patients with lamivudine‐resistant HBV and prevents graft reinfection with or without HBIg.

TL;DR: There was short-term histologic benefit to the use of this regimen, even in those patients without viral clearance, and post-OLT HCV recurrence can be safely treated with PEG-IFN and RIB.